HUL Acquires Full Stake in OZiva for ₹824 Cr, Divests Nutritionalab for ₹307 Cr
Hindustan Unilever Limited will acquire the remaining 49% stake in Zywie Ventures (OZiva) for ₹824 Crores, making it a wholly owned subsidiary. HUL will also divest its 19.8% stake in Nutritionalab for ₹307 Crores. Both transactions are expected to close by March 31, 2026.
The acquisition of full control over OZiva and the divestment of Nutritionalab are significant strategic decisions that will reshape HUL's Health & Wellbeing portfolio. The financial figures involved (₹824 Cr acquisition and ₹307 Cr divestment) indicate a material impact on the company's structure and focus.
The company is undertaking both an acquisition and a divestment, which are strategic moves. While the acquisition of OZiva aims for growth, the divestment of Nutritionalab is part of portfolio transformation. The net financial impact is not immediately clear, making the sentiment neutral.
Hindustan Unilever Limited (HUL) announced strategic moves in its Health & Wellbeing business on February 12, 2026. The Board of Directors approved the acquisition of the remaining 49% stake in Zywie Ventures Private Limited (OZiva) for a cash consideration of ₹824 Crores. Following this acquisition, Zywie and its subsidiary Zenherb Labs Private Limited will become wholly owned subsidiaries of HUL. The company also approved the sale of its entire 19.8% shareholding in Nutritionalab Private Limited to USV Private Limited for a consideration of ₹307 Crores. Zywie Ventures, incorporated in 2013, is involved in Vitamins, Minerals and Supplements, and Beauty and Personal Care products, with a turnover of ₹257.67 Crores in FY 2024-2025. Nutritionalab's revenue from operations for FY 2024-25 was ₹118.48 crores, and it is accounted for using the Equity method in HUL's consolidated financial statements. Both transactions are subject to the fulfillment of customary closing conditions and are expected to be completed by March 31, 2026. Priya Nair, CEO and Managing Director of HUL, stated that the full ownership of OZiva aims to unlock the next phase of growth in the Health & Wellbeing sector, reflecting HUL's strategy of focusing on fewer, bigger bets where its strengths can be leveraged.
What to do with a filing like this
Hindustan Unilever Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Hindustan Unilever Limited. Read the original for the full detail.